Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 2.5%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) traded down 2.5% during mid-day trading on Tuesday . The company traded as low as $0.24 and last traded at $0.24. 102,090 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 351,514 shares. The stock had previously closed at $0.24.

Theriva Biologics Price Performance

The stock has a market cap of $4.20 million, a PE ratio of -0.21 and a beta of 1.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.60 and a quick ratio of 3.60.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.